Clinical ink Expands Patient Engagement Solutions with Behavioral Diagnostic Tool SPUR™
Winston Salem, NC, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Clinical ink , a global life science technology company, is expanding its patient engagement suite with the inclusion of the SPUR behavioral diagnostic tool created by Observia .
- Winston Salem, NC, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Clinical ink , a global life science technology company, is expanding its patient engagement suite with the inclusion of the SPUR behavioral diagnostic tool created by Observia .
- SPUR TM is a behavioral diagnostic tool that is used to determine adherence to protocol and drugs, standardize lifestyle, and modify behavior by personalized intervention.
- The collaboration with Observia allows Clinical ink to capture a holistic view of patient behavior together with clinical outcomes and digital biomarkers.
- We strongly share Clinical ink’s vision that improving patient experience equals improving clinical trial performance,” says Kevin Dolgin , Head of R&D at Observia.